A game-changing new type of radiation therapy cuts time while improving precision in targeting tumors, a development that ...

As a caregiver, I learned that CyberKnife radiation for metastatic prostate cancer comes with psychological and physical ...

UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell ...

Emrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; ...

Once bound, the beta-minus emission from lutetium-177 delivers radiation to PSMA-expressing cells as well as surrounding cells, and induces DNA damage resulting in cell death. The primary endpoint ...

Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced financial ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

The experiments we have made have confirmed this anticipation, and shown that in every case in which light is scattered by the molecules in dust-free liquids or gases, the diffuse radiation of the ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Experts suggest that occurs when a person has a delayed hypersensitivity reaction to an antigen expressed after exposure to sunlight or artificial sources of ultraviolet (UV) radiation.

where they've begun receiving notices of dismissal in an overhaul ultimately expected to lay off up to 10,000 people Medical and parenting experts weigh in after study shows that women with ...

On track for multiple clinical updates through mid-2026, including further progress from two ongoing clinical programs and initiation of therapeutic dosing of potential new medicine, all based on our ...